Biosimilars offer a promising path to affordable, effective treatment, but barriers remain for underserved communities. This 2-part series explores the potential of biosimilars to improve health ...
Dive into biosimilar regulations in the US! Test your knowledge with our quiz on FDA rules, naming tricks, post-market safety, and more. Ready for the challenge?
Sarfaraz K. Niazi, PhD, explains FDA's new guidance on promotional labeling as well as challenges and insights into how this ...
On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from ...
Clinicians and a pharmacist discuss how they are managing access and assistance with copay assistance program in their practices.
Number 4: The FDA has granted approval for Shanghai Henlius Biotech’s trastuzumab biosimilar, Hercessi (trastuzumab-strf; HLX02), for the treatment of HER2-positive breast cancer. The approval marks ...
Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) ...
The FDA approved a high-concentration, citrate-free version of Boehringer Ingelheim’s Cyltezo (adalimumab-adbm), making it ...
April brought 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference. April brought 2 FDA approvals, 1 European approval, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results